相关实验视频

Updated: Jul 9, 2025

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring

Published on: May 17, 2024

在小鼠中,N1-甲基尼古丁胺胺会降低孕期葡萄糖耐受性

Xiaojing Wei^1,2,3, Yutian Tan^1,2,3, Jiaqi Huang⁴

¹Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.

Journal of molecular endocrinology

|November 29, 2023

概括

在孕期糖尿病模型中,N1-甲基尼古丁胺 (MNAM) 降低了葡萄糖耐受性. 在减少肝脂肪和脂肪组织炎症的同时,MNAM对葡萄糖代谢产生了负面影响,这表明在GDM治疗中要小心使用.

科学领域:

代谢研究的研究.
内分泌学在内分泌学.
营养科学营养科学

背景情况:

尼古丁胺的代谢物N1-甲基尼古丁胺 (MNAM) 在雄性动物中表现出抗糖尿病特性.
孕期糖尿病 (GDM) 对母亲和胎儿的健康构成风险.
了解GDM病理生理学和潜在的治疗干预措施至关重要.

研究的目的:

在GDM小鼠模型中研究MNAM对葡萄糖代谢的影响.
评估MNAM对肝脏脂质积累,脂肪组织和胎盘功能的影响.
阐明MNAM在妊娠期间对葡萄糖平衡的影响背后的分子机制.

主要方法:

在使用高脂肪饮食 (HFD) 的C57BL/6N小鼠中建立GDM模型.
给孕小鼠施用不同度的MNAM (0.3%或1%).
评估葡萄糖耐受性,胰岛素耐受性,肝脂含量,脂肪组织特征和骨肌肉,肝脏和胎盘中的分子标记物 (例如GLUT4,NAD+,GLUT1).

主要成果:

在对照和HFD养的小鼠中,MNAM补充剂降低了葡萄糖耐受性.
MNAM减少了肝脂积累和内脏脂肪组织质量和炎症.
MNAM降低了骨肌中的GLUT4表达和胎盘中的GLUT1,同时增强了肝脏葡萄糖生成.
胎盘体重,胎儿体重和 litter 尺寸没有受到影响.

结论:

MNAM的葡萄糖耐受性受损与骨肌肉GLUT4减少,肝脏葡萄糖生成增加和胎盘GLUT1减少有关.
尽管对肝脂肪和脂肪组织有有益影响,但MNAM对葡萄糖代谢的负面影响使得GDM治疗需要谨慎.
需要进一步的研究来澄清MNAM在妊娠代谢调节中的复杂作用.

关键词:

这是一种N1-甲基尼古丁胺胺.NAD+代谢 NAD+的代谢孕期糖尿病孕期糖尿病耐葡萄糖耐受性耐葡萄糖耐受性鼠标鼠标鼠标鼠标

更多相关视频

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

相关概念视频

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...